Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
| Revenue (Most Recent Fiscal Year) | $508.82M |
| Net Income (Most Recent Fiscal Year) | $-67.09M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 14.70 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 24.15 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -27.38% |
| Net Margin (Trailing 12 Months) | -27.70% |
| Return on Equity (Trailing 12 Months) | -64.60% |
| Return on Assets (Trailing 12 Months) | -17.22% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.80 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.75 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.01 |
| Inventory Turnover (Trailing 12 Months) | 1.47 |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.70 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.74 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.79 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 64.58M |
| Free Float | 61.86M |
| Market Capitalization | $8.26B |
| Average Volume (Last 20 Days) | 5.72M |
| Beta (Past 60 Months) | 0.84 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.21% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |